Key result
Levosimendan administration in children with severe heart failure improved ejection fraction from 29.8% to 40.5% (P=0.015) and allowed for catecholamine reduction.
Why the study?
Does Levosimendan improve ventricular function and reduce catecholamine requirements in critically ill children with severe heart failure?
Cohort (n=15)
No
Does Levosimendan improve ventricular function and reduce catecholamine requirements in critically ill children with severe heart failure?
Absolute Event Rate: 40.5% vs 29.8%
p-value: p=0.015
Levosimendan appears safe in children with severe heart failure and may facilitate the reduction of catecholamine support while improving myocardial performance, particularly in acute heart failure.
No takes yet. Share an insight, caveat, or question.
May support levosimendan in severe pediatric HF; leaves open confirmation in randomized trials.
Crossland et al. (2006) conducted a cohort in Severe myocardial dysfunction secondary to end-stage or acute heart failure (n=15). Levosimendan vs. Pre-Levosimendan baseline was evaluated on Ejection fraction (p=0.015). Levosimendan administration in children with severe heart failure improved ejection fraction from 29.8% to 40.5% (P=0.015) and allowed for catecholamine reduction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: